HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Protalix BioTherapeutics, Inc. (PLX)
2  -0.05  (-2.44%) 06-21 02:33
Open: 2.04 High: 2.05
Pre.close: 2.05 Low: 1.93
Volume: 3,260,096 Ave vol: 2,090,352
52w High: 7.02 52w Low: 1.93
MA(50): 2.637 MA(200): 4.095
EPS: -0.393 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protalix.com
Market Cap (M): 91
Shares Out (M): 45
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Technical analysis
Overall: Neutral
MA: Bearish MACD: Bullish
KDJ: Bearish RSI: Bearish
Target 1: 3.08 Target 2: 3.60
Resist 1: 2.64 Resist 2: 3.08
Support 1: 1.93 Support 2: 1.61
Company key metrics
Revenue per Share: 1.9139
Net Income per Share: -0.1985
Cash per Share: 1.1729
Book Value per Share: -0.8227
Price to Sales: 2.2885
Price to Book Value: -5.3239
Earnings Yield: -0.0453
Dividend Yield: 0
Debt to Equity: 0
Debt to Assets: 1.398
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Outperform
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.